Map Key
Generic Enzyme
Generic kinase
Protein kinase
Lipid kinase
Generic phosphatase
Protein phosphatase
Lipid phosphatase
Generic phospholipase
Generic protease
Metalloprotease
G-alpha
RAS - superfamily
G beta/gamma
Regulators (GDI, GAP, GEF)
Generic channel
Ligand-gated channel
Voltage-gated channel
Transporter
Normal process
Pathological process
Positive effect
Negative effect
Unspecified effect
Technical link
Disrupts in disease
Emerges in disease
Enhances in disease
Weakens in disease
Organsim specific interaction

Generic binding protein
Receptor ligand
Cell membrane glycoprotein
Transcription factor
DNA
RNA
Compound
Inorganic ion
Predicted metabolite or user's structure
Reaction
Generic receptor
GPCR
Receptors with enzyme activity
Mitochondria
EPR
Golgi
Nucleus
Lysosome
Peroxisome
Cytoplasm
Extracellular

Normal process
Pathological process
Binding
Cleavage
Covalent modifications
Phosphorylation
Dephosphorylation
Transformation
Transport
Catalysis
Transcription regulation
MicroRNA binding
Competition
Influence on expression
Unspecified interactions
Pharmacological effect
Toxic effect
Group relation
Complex subunit
Similarity reaction
A complex or a group
Organism specific object

Development Ligand-independent activation of ESR1 and ESR2


Log In to Post A Comment

Development Ligand-independent activation of ESR1 and ESR2

Ligand-independent activation of ESR1 and ESR2

In addition to the conventional hormone-dependent regulation of activity of Estrogenreceptor alpha and beta ( ESR1(nuclear) and ESR2 respectively), there is across-talk between signal transduction pathways and estrogen receptors [1].Epidermal growth factor ( EGF ), Insulin-like growth factor-1 ( IGF-1 ),stimulators of cAMP-dependent signaling pathway regulate transcriptional activity of theESR1(nuclear) and ESR2 in the absence of ligand [2], [3], [4]. Regulators of ESR1 (nuclear) and ESR2transcriptional activity activate multiple signaling pathways.

EGF and IGF-1 activate ESR1(nuclear) by binding to thecorresponding receptors (Epidermal growth factor receptor ( EGFR ) andInsulin-like growth factor 1 receptor ( IGF-1 receptor ) respectively) followed bystimulation of mitogen-activated protein kinases (MAPK) cascade - signaling pathway.ESR2 is activated only by EGF signaling [5], [6].The adaptors Src homology 2 domain-containing transforming protein 1 ( Shc ) andGrowth factor receptor-bound protein 2 ( Grb2 ) recruit exchange factor Son ofsevenless homolog ( SOS ), forming a protein complex Shc/ Grb2/SOS. Activated SOS stimulates small GTPase v-Ha-ras Harvey rat sarcomaviral oncogene homolog ( H-Ras ) by its conversion from the inactive GDP-boundingstate to the active GTP-bounding state. The activated H-RAS stimulates v-raf-1murine leukemia viral oncogene homolog 1 ( c-Raf-1 )/ Mitogen-activated proteinkinase kinases 1 and 2 ( MEK1(MAP2K1) MEK2(MAP2K2) )/ Mitogen activated proteinkinases 1-3 ( ERK1/2 ) cascade, which leads to higher transcriptional activity ofESR1 (nuclear) and ESR2. ERK1/2 can activate ESR1 (nuclear)and ESR2 by direct phosphorylation [5], [7], [8] or via phosphorylation of coregulatory proteins such as Nuclear receptorco-activators 1, 2 and 3 ( NCOA1 (SRC1), NCOA2 (GRIP1/TIF2) and NCOA3(pCIP/SRC3), respectively) [9], [10], [11].

EGF also activates Ribosomal protein S6 kinase, 90kDa, polypeptide 1 (p90RSK1 ) (most probably through MAP kinases pathway), which phosphorylates andenhances transcriptional activity of ESR1 (nuclear) [12], [8] .

The second pathway which stimulates exclusively ESR1 (nuclear) by EGFand IGF-1 includes activation Phosphoinositide-3-kinase ( PI3K )/ V-aktmurine thymoma viral oncogene homolog 1 ( AKT(PKB) ) cascade. EGFR(directly) and IGF-1 receptor (via Insulin receptor substrate 1 ( IRS-1 ))activate PI3K which converts phosphatidylinositol 4,5-biphosphate (PtdIns(4,5)P2 ) to phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P3 ). PtdIns(3,4,5)P3 associates with the inner face of theplasma membrane promoting the recruitment and activation of the AKT(PKB). BothPI3K and AKT(PKB) phosphorylate ESR1 (nuclear) [13],[14], [8], [15].

Neuregulin-1 also activates ESR1 (nuclear) in aligand-independent manner via PI3K/ AKT(PKB) pathway. Neuregulin-1interacts with an v-erb-b2 erythroblastic leukemia viral oncogene homolog 2,neuro/glioblastoma derived oncogene homolog of ( ErbB2 )/ v-erb-b2 erythroblasticleukemia viral oncogene homolog 3 ( ErbB3 ) heterodimers; activated ErbB3recruits and activates PI3K and, consequently, AKT(PKB) and ESR1(nuclear) phosphorylated by AKT(PKB) [16].

Stimulation of cAMP/ Protein kinase, cAMP-dependent ( PKA ) signalinglikely proceeds via G-protein alpha-s which activates Adenylate cyclase.Activation of PKA by cAMP is the third ligand-independent signaling pathwaywhich stimulates ESR1 (nuclear) [2], [8], [15].

During stimulation of cAMP signaling pathway, coactivator Cyclin D1enhances transcriptional activity of ESR1 (nuclear) in a ligand-independent manner[17], [1].

Co-regulatory proteins NCOA1 (SRC1), NCOA2 (GRIP1/TIF2) and NCOA3(pCIP/SRC3) in response to growth factors overall ligand-independent ESR activationmay be due to more efficient recruitment of coactivators to the ESR1 (nuclear) andESR2 [10], [18], [19]. Phosphorylation ofESR1 (nuclear) increases affinity of coactivators such as NCOA3 [15]. ESR1 (nuclear) -coactivator complex then recruits integratorproteins such as CREB binding protein ( CBP ) and E1A binding protein p300 (p300 ), which by DNA looping brings the receptor-containing regulatory region ofthe gene into proximity with the actual transcriptional start site [10],[18].

Caveolin 1, caveolae protein, 22kDa ( Caveolin-1 ) is yet another co-activatorof ESR1 (nuclear) in a ligand-independent manner, which drives ERK-independent phosphorylation and activation of AF-1 domain [20].

Ligand-independent transcriptional activation of ERS1 (nuclear) and ESR2pathways results in transcription of Trefoil-factor protein 1 ( TFF1 ) [21], [14], [18]. TFF1 display a great number ofphysiological actions [22], [23], [24]. Its role inligand-independent ESR activation is not yet resolved. ERS1 (nuclear) andESR2 inhibit cell migration and invasion and ESR2 inhibits cellproliferation in a ligand-independent manner [25], [26].